Albireo   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Gothenburg Sweden (2008)

Organization Overview

First Clinical Trial
2009
NCT01007123
First Marketed Drug
2021
a4250
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Albireo | ALBIREO

Active Ingredients

Marketed Drugs (1)

a4250 (2021)

Drugs in Phase 3 Trials (4)

Key: Albireo (1) Acquired (3)

a4250 (11 trials)

insulin glargine (toujeo) (7 trials)

insulin human (humulin) (10 trials)

insulin lispro (humalog) (12 trials)

Drugs in Phase 2 Trials (2)

a3384 (1 trial)

elobixibat (3 trials)

Drugs in Phase 1 Trials (2)

Key: Albireo (1) Acquired (1)

cholestyramine (questran) (1 trial)

glucagon (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alagille Syndrome (Phase 3)

Biliary Atresia (Phase 3)

Cholestasis (Phase 3)

Cholestasis, Intrahepatic (Phase 3)

Constipation (Phase 2)

Dyslipidemias (Phase 2)

Fibrosis (Phase 2)

Liver Cirrhosis (Phase 2)

Liver Cirrhosis, Biliary (Phase 2)

Liver Diseases (Phase 1)

Malabsorption Syndromes (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Pruritus (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 32
  • # of Trial APIs: 8